Myelodysplastic Syndrome Drugs Market Growth & Trends
The global myelodysplastic syndrome drugs market size is expected to reach USD 5.28 billion by 2030, exhibiting at a CAGR of 9.1% from 2024 to 2030. Factors such as strong product pipeline, rising geriatric population, and favorable government initiatives are driving the market.
MDS is caused by mutation of one or more genes that control development of blood cells. Patients with this condition may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Although majority of cases (over 90%) are reported in people over the age of 60, the condition can occur at any age, more frequently in men than in women. About 30% of MDS cases advance to acute myeloid leukemia (AML).
The immunomodulatory drug segment is expected to retain its dominant position in the MDS drugs market due to strong sales of Revlimid. Supported by potential approvals of luspatercept and Aranesp, the anti-anemics drug segment is forecast to gain higher market share than hypomethylating agents, thus contributing significantly to the overall expansion of the market.
Developing novel drugs for the treatment of rare subsets of MDS patients is a key challenge as the disease is highly heterogeneous at the molecular level. In addition, morbidity issues and poor quality of life due to incapacitating effects of the standard of care treatment paradigms are causes of inconvenience for geriatric population.
Myelodysplastic Syndrome Drugs Market Report Highlights
- Stem cell transplant dominated the market and accounted for a share of 38.7% in 2023. Stem transplants use stem cells from healthy donors to replace damaged bone marrow. Stem cell transplant has the potential to restore the bone marrow damaged from high chemotherapy doses or from radiation therapy.
- Oral route of administration accounted for the largest market revenue share of 59.5% in 2023. The advantages of oral medicines, such as tablets and the elimination of injection-associated adverse events, are a few factors driving the market growth.
- The hospital segment accounted for the largest market revenue share of 48.6% in 2023. The rising prevalence of chronic diseases is driving hospitals to provide a concentrated treatment that cannot be treated at home.
- North America’s myelodysplastic syndromes drugs market dominated with revenue share of 35.44% in 2023. This growth is attributed to the growing geriatric population and growing incidences of myelodysplastic syndrome (MDS).
- The Asia Pacific myelodysplastic syndrome drugs market is estimated to register the fastest CAGR over the forecast period. The growth is primarily attributed to the rising geriatric population and advancements by companies and research institutions.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Myelodysplastic Syndrome Drugs Market Variables, Trends, & Scope
Chapter 4. Myelodysplastic Syndrome Drugs Market: Product Estimates & Trend Analysis
Chapter 5. Myelodysplastic Syndrome Drugs Market: Application Estimates & Trend Analysis
Chapter 6. Myelodysplastic Syndrome Drugs Market: End Use Estimates & Trend Analysis
Chapter 7. Myelodysplastic Syndrome Drugs Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
- Celgene Corporation (Bristol-Myers Squibb company)
- Otsuka Pharmaceutical Co. Ltd
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Takeda Pharmaceutical Company Ltd
- Mylan N.V.
- Cipla Pharmaceutical Limited
- Onconova Therapeutics
- Hikma Pharmaceuticals PLC
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | August 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 2.88 Billion |
| Forecasted Market Value ( USD | $ 5.28 Billion |
| Compound Annual Growth Rate | 9.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
